

---

# A Study of CYTOKERATIN 19 FRAGMENT (CYFRA 21-1) IN SOME CASES WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASES


---

## Thesis

*Submitted for Partial Fulfillment of  
Master Degree in Chest Diseases*

**By**

Ashraf Mokhtar Madkour  
*M.B., B.Ch.*



616:99224  
A. M

**Supervised By**

Professor Doctor  
**HUSSEIN ALY HUSSEIN**


*Professor of Chest Diseases  
Faculty of Medicine, Ain Shams University*

53760

*[Handwritten signature]*

Professor Doctor  
**MOHAMED AWAD TAG-ELDIN**  
*Professor of Chest Diseases & Vice President  
of Ain Shams University*

Professor Doctor  
**ALY KHALIFA ALY**  
*Professor of Biochemistry  
Faculty of Medicine, Ain Shams University*



*Fathy Tard*


FACULTY OF MEDICINE

1997

AIN SHAMS UNIVERSITY







1. The first part of the document is a list of references. The references are listed in a standard format, including the author's name, the title of the work, and the publisher. The references are as follows:

---

# ACKNOWLEDGEMENT

Thanks to **GOD** who offered me the ability to perform the work of this thesis.

I would like to express my deepest thanks and gratitude to **Professor Dr. Hussein Aly Hussein**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his great help valuable criticism and continuous encouragement throughout the whole research. I am very much privileged and honoured to have him as my supervisor.

I am very much obliged to the kindness and great help of **Professor Dr. Mohamed Awad Tag El Din**, Professor of Chest Diseases, Faculty of Medicine and Vice President of Ain Shams University, for his kind guidance, valuable support, sincere directions and encouragement throughout the work.

My deepest thanks and gratitude to **Professor Dr. Aly Khalifa Aly**, Professor of Biochemistry Faculty of Medicine, Ain Shams University. I thank him deeply for the help he provided me during the production of this thesis.

Many thanks are directed to **Dr. Mahmoud Abd El-Wahab** from Oncology diagnostic Unit, Faculty of Medicine, Ain Shams University for his kind help through the practical part of this thesis. Finally, I am very grateful to all the **Staff of Chest Department**, Ain Shams University for their help and cooperation.

---

1. The first part of the document is a title page. It contains the title of the document, the author's name, and the date of the document. The title is "The History of the World". The author is "John Smith". The date is "1607".

---

# CONTENTS

Introduction and Aim of the Work	1
Review of Literature	4
Chronic Obstructive Pulmonary Disease (C.O.P.D.)	4
Introduction	4
Definitions	6
Epidemiology	12
Risk Factors for C.O.P.D.	15
Natural History of C.O.P.D.	26
Pathology and Pathophysiology	28
Clinical features	39
Laboratory Investigations and Diagnostic Tests	42
Prognosis	60
Higher Risk of Lung Cancer in C.O.P.D.	64
Tumor Markers	66
Introduction and definition	66
Classification of tumor markers	67
Tumor markers in lung cancer	69
Cytokeratins	71
CYFRA 21-1	79
Subjects and Methods	84
Results	93
Discussion	110
Summary and Conclusion	127
Recommendations	123
Appendix.	
References	124
Arabic Summary.	

---



.....

.....

---

# LIST OF ABBREVIATIONS

ABG	Arterial blood gases
AFP	Alpha fetoprotein
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
ATS	American Thoracic Society
ATT	Alpha <sub>1</sub> - antitrypsin
C.O.P.D.	Chronic Obstructive Pulmonary Disease
CEA	Carcinoembryonic antigen
CKs	Cytokeratins
CT	Computed tomography
CYFRA 21-1	Cytokeratin 19 fragment
ECG	Electrocardiography
EGF	Epidermal growth factor
EIA	Enzyme immunoassay
ELISA	Enzyme linked immunoassay
FEF <sub>25-75%</sub> of pred.	Average flow rate between 25% and 75% of the forced vital capacity
FEV <sub>1</sub>	Forced expiratory volume in one second
FEV <sub>1</sub> /FVC% of pred.	Ratio of FEV <sub>1</sub> to FVC expressed as a percentage of predicted
FRC	Functional residual capacity
FVC	Forced vital capacity
G.O.L.D.	Generalized obstructive lung disease
IgE	Immunoglobulin E
KCO	Diffusion coefficient, or Transfer coefficient

---

---

<b>KD</b>	Kilo dalton
<b>MoAbs</b>	Monoclonal antibodies
<b>MW</b>	Molecular weight
<b>min</b>	minutes
<b>NSCLC</b>	Non small cell lung cancer
<b>NSE</b>	Neurone specific enolase
<b>PaCO<sub>2</sub></b>	Arterial carbon dioxide tension
<b>PaO<sub>2</sub></b>	Arterial oxygen tension
<b>PEEPi</b>	Intrinsic positive end expiratory pressure
<b>PEF</b>	Peak expiratory flow
<b>PE<sub>max</sub></b>	Maximum expiratory pressure
<b>PI<sub>max</sub></b>	Maximum inspiratory pressure
<b>pH</b>	Negative log of the hydrogen ion concentration
<b>REM</b>	Rapid eye movement
<b>RV</b>	Residual volume
<b>SaO<sub>2</sub></b>	Arterial oxygen saturation
<b>SCC-Ag</b>	Squamous cell carcinoma antigen
<b>SCLC</b>	Small cell lung cancer
<b>SGOT</b>	Serum glutamic oxaloacetic transaminase
<b>SGPT</b>	Serum glutamic pyruvic transaminase
<b>TLC</b>	Total lung capacity
<b>TLCO</b>	Carbon monoxide transfer factor
<b>TPA</b>	Tissue polypeptide antigen
<b>V'/Q'</b>	Ventilation/Perfusion ratio
<b>V'<sub>max</sub></b>	Maximal expiratory flow at a given lung volume
<b>V'<sub>max 50</sub></b>	Maximal expiratory flow at 50% of vital capacity
<b>VC</b>	Vital capacity
<b>WHO</b>	World Health Organization

---

# LIST OF TABLES

<b>Table 1:</b> Risk factors of C.O.P.D.	25
<b>Table 2:</b> Severity of C.O.P.D. based on FEV <sub>1</sub>	47
<b>Table 3:</b> Investigations for diagnosis and initial assessment.	58
<b>Table 4:</b> Diagnosis of C.O.P.D.	59
<b>Table 5:</b> Comparison between control group and C.O.P.D. non hypoxic group as regard: spirometric functions, ABGs and CYFRA 21-1 levels.	102
<b>Table 6:</b> Comparison between control group and C.O.P.D. hypoxic as regard: spirometric functions, ABGs and CYFRA 21-1 levels.	103
<b>Table 7:</b> Comparison between C.O.P.D. hypoxic group and non-hypoxic group as regard: spirometric functions, ABGs and CYFRA 21-1 levels.	104
<b>Table 8:</b> Comparison between C.O.P.D. hypoxic before and after treatment as regard: spirometric functions, ABGs and CYFRA 21-1 levels.	105
<b>Table 9:</b> Comparison between Non small cell lung cancer group and C.O.P.D. hypoxic group as regard: spirometric functions, ABGs and CYFRA 21-1 levels.	106
<b>Table 10:</b> Summary of results of CYFRA 21-1 level in studied groups.	107
<b>Table 11:</b> Comparison of CYFRA 21-1 level in studied groups.	107
<b>Table 12:</b> Comparison between FEV <sub>1</sub> % of predicted: PaO <sub>2</sub> , PaCO <sub>2</sub> and different levels of CYFRA 21-1 in C.O.P.D. hypoxic group using correlation coefficient (r) test.	108
<b>Table 13:</b> Cases above and below out of value (3.2 ng/ml) in control, C.O.P.D. hypoxic, C.O.P.D. non hypoxic and N.S.C.L.C. groups with sensitivity and specificity of CYFRA 21-1.	109

2017/2018

1

---

## Appendix

**Table 14:** Showing age, spirometric functions, ABGs, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), serum creatinine and CYFRA 21-1 levels in control group.

**Table 15:** Showing age, smoking index, spirometric functions, ABGs, SGOT, SGPT, serum creatinine and CYFRA 21-1 levels in C.O.P.D. non hypoxic group.

**Table 16:** Showing age, smoking index, spirometric functions, ABGs, SGOT, SGPT, serum creatinine and CYFRA 21-1 levels in C.O.P.D. non-hypoxic group before and after treatment.

**Table 17:** Showing age, smoking index, spirometric functions ABGs, SGOT, SGPT, serum creatinine and CYFRA 21-1 levels in non small cell lung cancer (N.S.C.L.C.) group.

2024/01/01 10:00 AM - 10:05 AM

1